Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bumble Inc (BMBL) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Bumble IncTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Bumble Inc vs Charles River Laboratories Intl. Inc — how do they compare? Bumble Inc trades at $2.62 (market cap $366.87M), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 36.7× Bumble Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.

BMBLCRL
Market Cap
$366.87M$13.46B
Sector
TechnologyHealth
52-Week High
$7.17$282.00
52-Week Low
$2.70$145.57
Enterprise Value
$672.73M$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bumble Inc

Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.

The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bumble Inc

Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.

Read more on BMBL

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL